


EGFR Inh. | Erlotinib | Tarceva® |
Lapatinib | Tykerb® | |
Gefitinib | Iressa® | |
Cetuximab | Erbitux® | |
Panitumumab | Vectibix® | |
BRAF Inh. | Vemurafenib | Zelboraf® |
Dabrafenib | Tafinlar® | |
MEK Inh. | Trametinib | Mekinist® |
Cobimetinib | Cotellic® | |
Multikinase Inh. | Sorafenib | Nexavar® |
Sunitinib | Sutent® | |
Axitinib | Inlyta® | |
Pazopanib | Votrient® | |
mTOR Inh. | Everolimus | Afinitor® |
Temsirolimus | Torisel® | |
PI3K Inh. | Idelalisib | Zydelig® |
cKIT Inh. | Imatinib | Gleevec® |
Anti-CTLA-4-Ak | Ipilimumab | Yervoy® |
Anti-PD1-Ak | Nivolumab | Opdivo® |
Pembrolizumab | Keytruda® |
Dr. Katja Schindler
Fichtegasse 5/8
1010 Wien
+43 (0) 1 226 4444
Copyright © Dr. Katja Schindler